COMP <GO>
XERS vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Xeris Biopharma Holdings Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: XERS 1
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $10.75 (+1.03%) • MKT CAP: $1.96B
roic
16.00%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XERS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.00% | 25.50% | -9.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 83.1x | 18.5x | +64.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.46% | 2.97% | -1.51 | JNJ | /fcf-yield <GO> |
| Operating Margin | 8.50% | 34.70% | -26.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.20% | 28.50% | -28.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 43.70% | 6.00% | +37.70 | XERS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.11 | 5.59 | -3.48 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 62.1 | -2.08 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.96B | $662.49B | -$660.53B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XERS REV | JNJ REV | XERS GROSS % | JNJ GROSS % | XERS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $291.8M | $94.19B | — | 67.9% | $28.6M | $19.70B |
| FY 2024 | $203.1M | $88.82B | — | 69.1% | -$37.0M | $19.84B |
| FY 2023 | $163.9M | $85.16B | — | — | -$47.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
JNJ // BETA 1.08